LIVIVO - Search results -

Search results

Result 1 - 10 of total 25

Search options

Article ; Online: Correção de defeito ósseo femural em cães utilizando implante cortical homólogo conservado em mel

Amendola Gustavo Frassetto / Ilha Márcia / Berger Raquel / Stedile Rafael / Schossler João Eduardo

Acta Cirurgica Brasileira, Vol 18, Iss 4, Pp 302-

2003 Volume 307

Abstract: OBJETIVO: Avaliar a utilização de osso canino conservado em mel como implante em defeitos ósseos ... implantado. CONCLUSÃO: O mel pode ser adequado como conservante de ossos. ...

Abstract	OBJETIVO: Avaliar a utilização de osso canino conservado em mel como implante em defeitos ósseos criados em fêmures de cães. MÉTODOS: Doze caninos adultos foram submetidos a remoção de um segmento ósseo retangular compreendendo um terço do diâmetro do osso por 2cm de comprimento da diáfise femural. Posteriormente foram inseridos dois pinos intramedulares e fixado um implante ósseo conservado de tamanho compatível com o defeito através de cerclagem com fio de aço. Os animais foram avaliados radiograficamente no dia da intervenção cirúrgica e aos 30 e 60 dias. RESULTADOS: Após o final dos 60 dias foi possível verificar incorporação do implante em oito animais enquanto que em quatro houve reabsorção do material implantado. CONCLUSÃO: O mel pode ser adequado como conservante de ossos.
Keywords	Ortopedia ; Caninos ; Enxerto cortical ; Mel ; Surgery ; RD1-811 ; Medicine ; R ; DOAJ:Surgery ; DOAJ:Medicine (General) ; DOAJ:Health Sciences
Language	English
Publishing date	2003-01-01T00:00:00Z
Publisher	Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Gender, Parenthood, and the Medical Record.

Berger, Mel

The journal of allergy and clinical immunology. In practice

2019 Volume 8, Issue 2, Page(s) 750–751

MeSH term(s)	Medical Records ; Parenting ; Reproductive Techniques, Assisted
Language	English
Publishing date	2019-11-02
Publishing country	United States
Document type	Editorial ; Comment
ZDB-ID	2843237-X
ISSN	2213-2201 ; 2213-2198
ISSN (online)	2213-2201
ISSN	2213-2198
DOI	10.1016/j.jaip.2019.08.021
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 7086: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Review and assessment of the donor safety among plasma donors.

Purohit, Mitali / Berger, Mel / Malhotra, Rachpal / Simon, Toby

Transfusion

2023 Volume 63, Issue 6, Page(s) 1230–1240

MeSH term(s)	Humans ; Blood Donors ; Living Donors
Language	English
Publishing date	2023-04-19
Publishing country	United States
Document type	Journal Article ; Review ; Research Support, Non-U.S. Gov't
ZDB-ID	208417-x
ISSN	1537-2995 ; 0041-1132
ISSN (online)	1537-2995
ISSN	0041-1132
DOI	10.1111/trf.17369
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 284: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Correção de defeito ósseo femural em cães utilizando implante cortical homólogo conservado em mel Femoral bone defect reparation in dogs with homolog cortical graft preserved in honey

Gustavo Frassetto Amendola / Márcia Ilha / Raquel Berger / Rafael Stedile / João Eduardo Schossler

Acta Cirurgica Brasileira, Vol 18, Iss 4, Pp 302-

2003 Volume 307

Abstract: OBJETIVO: Avaliar a utilização de osso canino conservado em mel como implante em defeitos ósseos ... implantado. CONCLUSÃO: O mel pode ser adequado como conservante de ossos. PURPOSE: Evaluate the use of canine ...

Abstract	OBJETIVO: Avaliar a utilização de osso canino conservado em mel como implante em defeitos ósseos criados em fêmures de cães. MÉTODOS: Doze caninos adultos foram submetidos a remoção de um segmento ósseo retangular compreendendo um terço do diâmetro do osso por 2cm de comprimento da diáfise femural. Posteriormente foram inseridos dois pinos intramedulares e fixado um implante ósseo conservado de tamanho compatível com o defeito através de cerclagem com fio de aço. Os animais foram avaliados radiograficamente no dia da intervenção cirúrgica e aos 30 e 60 dias. RESULTADOS: Após o final dos 60 dias foi possível verificar incorporação do implante em oito animais enquanto que em quatro houve reabsorção do material implantado. CONCLUSÃO: O mel pode ser adequado como conservante de ossos. PURPOSE: Evaluate the use of canine bone conserved in honey as graft in the correction of bone defects in dogs. METHODS: Twelve mongrel dogs were used, male and female, weighing between 6 and 15 kg, comprising a single experimental group. After, the left femur was accessed in the lateral side of its shaft and a segment of two centimeters length by one third of the diameter was removed. Two intrammedulary Steinman pins were inserted by normograde way and the defect was covered with the bone graft and fixed with cerclage wire. The animals were radiographically evaluated in the day of the surgery, 30 and 60 days after. RESULTS: By the end of the 60 days these dogs were euthaniezed for gross and microscopycal evaluation. Eight animals presented the incorporation of the graft and the other four had bone resorption in the inplantation site. CONCLUSION: The bone preserved in honey is able to be used in bone grafting.
Keywords	Ortopedia ; Caninos ; Enxerto cortical ; Mel ; Orthopedy ; Canine ; Bone grafting ; Honey ; Surgery ; RD1-811 ; Medicine ; R ; DOAJ:Surgery ; DOAJ:Medicine (General) ; DOAJ:Health Sciences
Subject code	630
Language	English
Publishing date	2003-08-01T00:00:00Z
Publisher	Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Update on C1 Esterase Inhibitor in Human Solid Organ Transplantation.

Berger, Mel / Lefaucheur, Carmen / Jordan, Stanley C

Transplantation

2019 Volume 103, Issue 9, Page(s) 1763–1775

Abstract: Complement plays important roles in both ischemia-reperfusion injury (IRI) and antibody-mediated rejection (AMR) of solid organ allografts. One approach to possibly improve outcomes after transplantation is the use of C1 inhibitor (C1-INH), which blocks ... ...

Abstract	Complement plays important roles in both ischemia-reperfusion injury (IRI) and antibody-mediated rejection (AMR) of solid organ allografts. One approach to possibly improve outcomes after transplantation is the use of C1 inhibitor (C1-INH), which blocks the first step in both the classical and lectin pathways of complement activation and also inhibits the contact, coagulation, and kinin systems. C1-INH can also directly block leukocyte-endothelial cell adhesion. C1-INH contrasts with eculizumab and other distal inhibitors, which do not affect C4b or C3b deposition or noncomplement pathways. Authors of reports on trials in kidney transplant recipients have suggested that C1-INH treatment may reduce IRI and delayed graft function, based on decreased requirements for dialysis in the first month after transplantation. This effect was particularly marked with grafts with Kidney Disease Profile Index ≥ 85. Other clinical studies and models suggest that C1-INH may decrease sensitization and donor-specific antibody production and might improve outcomes in AMR, including in patients who are refractory to other modalities. However, the studies have been small and often only single-center. This article reviews clinical data and ongoing trials with C1-INH in transplant recipients, compares the results with those of other complement inhibitors, and summarizes potentially productive directions for future research.
MeSH term(s)	Allografts ; Animals ; Complement Activation/drug effects ; Complement C1 Inhibitor Protein/adverse effects ; Complement C1 Inhibitor Protein/therapeutic use ; Complement C1s/antagonists & inhibitors ; Complement C1s/immunology ; Complement Inactivating Agents/adverse effects ; Complement Inactivating Agents/therapeutic use ; Delayed Graft Function/immunology ; Delayed Graft Function/prevention & control ; Graft Rejection/immunology ; Graft Rejection/prevention & control ; Graft Survival/drug effects ; Humans ; Organ Transplantation/adverse effects ; Reperfusion Injury/immunology ; Reperfusion Injury/prevention & control ; Risk Factors ; Treatment Outcome
Chemical Substances	Complement C1 Inhibitor Protein ; Complement Inactivating Agents ; Complement C1s (EC 3.4.21.42)
Language	English
Publishing date	2019-04-16
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	208424-7
ISSN	1534-6080 ; 0041-1337
ISSN (online)	1534-6080
ISSN	0041-1337
DOI	10.1097/TP.0000000000002717
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 488: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 509: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Chronic Active Antibody-mediated Rejection: Opportunity to Determine the Role of Interleukin-6 Blockade.

Berger, Mel / Baliker, Mary / Van Gelder, Teun / Böhmig, Georg A / Mannon, Roslyn B / Kumar, Deepali / Chadban, Steve / Nickerson, Peter / Lee, Laurie A / Djamali, Arjang

Transplantation

2023 Volume 108, Issue 5, Page(s) 1109–1114

Abstract: Chronic active antibody-mediated rejection (caAMR) is arguably the most important cause of late kidney allograft failure. However, there are no US Food and Drug Administration (FDA)-approved treatments for acute or chronic AMR and there is no consensus ... ...

Abstract	Chronic active antibody-mediated rejection (caAMR) is arguably the most important cause of late kidney allograft failure. However, there are no US Food and Drug Administration (FDA)-approved treatments for acute or chronic AMR and there is no consensus on effective treatment. Many trials in transplantation have failed because of slow and/or inadequate enrollment, and no new agent has been approved by the FDA for transplantation in over a decade. Several lines of evidence suggest that interleukin-6 is an important driver of AMR, and clazakizumab, a humanized monoclonal antibody that neutralizes interleukin-6, has shown promising results in phase 2 studies. The IMAGINE trial (Interleukin-6 Blockade Modifying Antibody-mediated Graft Injury and Estimated Glomerular Filtration Rate Decline) (NCT03744910) is the first to be considered by the FDA using a reasonably likely surrogate endpoint (slope of estimated glomerular filtration rate decline >1 y) for accelerated approval and is the only ongoing clinical trial for the treatment of chronic rejection. This trial offers us the opportunity to advance the care for our patients in need, and this article is a call to action for all transplant providers caring for patients with caAMR.
MeSH term(s)	Humans ; Graft Rejection/immunology ; Graft Rejection/prevention & control ; Interleukin-6/antagonists & inhibitors ; Interleukin-6/immunology ; Kidney Transplantation/adverse effects ; Chronic Disease ; Antibodies, Monoclonal, Humanized/therapeutic use ; Glomerular Filtration Rate/drug effects ; Immunosuppressive Agents/therapeutic use ; Treatment Outcome ; Isoantibodies/immunology ; Graft Survival/drug effects
Chemical Substances	Interleukin-6 ; Antibodies, Monoclonal, Humanized ; Immunosuppressive Agents ; Isoantibodies
Language	English
Publishing date	2023-11-09
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	208424-7
ISSN	1534-6080 ; 0041-1337
ISSN (online)	1534-6080
ISSN	0041-1337
DOI	10.1097/TP.0000000000004822
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 488: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 509: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Correction to: Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials.

Ballow, Mark / Wasserman, Richard L / Jolles, Stephen / Chapel, Helen / Berger, Mel / Misbah, Siraj A

Journal of clinical immunology

2018 Volume 38, Issue 4, Page(s) 539

Abstract: ... in Clinical Trials, written by Mark Ballow, Richard L. Wasserman, Stephen Jolles, Helen Chapel, Mel Berger, Siraj ...

Abstract	The article Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials, written by Mark Ballow, Richard L. Wasserman, Stephen Jolles, Helen Chapel, Mel Berger, Siraj A. Misbah, was originally published Online First without open access.
Language	English
Publishing date	2018-03-11
Publishing country	Netherlands
Document type	Published Erratum
ZDB-ID	779361-3
ISSN	1573-2592 ; 0271-9142
ISSN (online)	1573-2592
ISSN	0271-9142
DOI	10.1007/s10875-018-0504-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1640: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Alpha-1-antitrypsin in cell and organ transplantation.

Berger, Mel / Liu, Mingyao / Uknis, Marc E / Koulmanda, Maria

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

2018 Volume 18, Issue 7, Page(s) 1589–1595

Abstract: Limited availability of donor organs and risk of ischemia-reperfusion injury (IRI) seriously restrict organ transplantation. Therapeutics that can prevent or reduce IRI could potentially increase the number of transplants by increasing use of borderline ... ...

Abstract	Limited availability of donor organs and risk of ischemia-reperfusion injury (IRI) seriously restrict organ transplantation. Therapeutics that can prevent or reduce IRI could potentially increase the number of transplants by increasing use of borderline organs and decreasing discards. Alpha-1 antitrypsin (AAT) is an acute phase reactant and serine protease inhibitor that limits inflammatory tissue damage. Purified plasma-derived AAT has been well tolerated in more than 30 years of use to prevent emphysema in AAT-deficient individuals. Accumulating evidence suggests that AAT has additional anti-inflammatory and tissue-protective effects including improving mitochondrial membrane stability, inhibiting apoptosis, inhibiting nuclear factor kappa B activation, modulating pro- vs anti-inflammatory cytokine balance, and promoting immunologic tolerance. Cell culture and animal studies have shown that AAT limits tissue injury and promotes cell and tissue survival. AAT can promote tolerance in animal models by downregulating early inflammation and favoring induction and stabilization of regulatory T cells. The diverse intracellular and immune-modulatory effects of AAT and its well-established tolerability in patients suggest that it might be useful in transplantation. Clinical trials, planned and/or in progress, should help determine whether the promise of the animal and cellular studies will be fulfilled by improving outcomes in human organ transplantation.
MeSH term(s)	Animals ; Apoptosis ; Cytokines/metabolism ; Humans ; Inflammation/prevention & control ; NF-kappa B/metabolism ; Organ Transplantation ; Reperfusion Injury/immunology ; Reperfusion Injury/metabolism ; Reperfusion Injury/prevention & control ; Serine Proteinase Inhibitors/pharmacology ; alpha 1-Antitrypsin/pharmacology
Chemical Substances	Cytokines ; NF-kappa B ; Serine Proteinase Inhibitors ; alpha 1-Antitrypsin
Language	English
Publishing date	2018-04-24
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	2060594-8
ISSN	1600-6143 ; 1600-6135
ISSN (online)	1600-6143
ISSN	1600-6135
DOI	10.1111/ajt.14756
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5542: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials.

Ballow, Mark / Wasserman, Richard L / Jolles, Stephen / Chapel, Helen / Berger, Mel / Misbah, Siraj A

Journal of clinical immunology

2017 Volume 37, Issue 6, Page(s) 517–518

MeSH term(s)	Clinical Trials as Topic ; Drug-Related Side Effects and Adverse Reactions ; Humans ; Immunoglobulin G/therapeutic use ; Immunologic Deficiency Syndromes/drug therapy ; Immunosuppressive Agents/therapeutic use ; Injections, Subcutaneous ; North America ; Research Design
Chemical Substances	Immunoglobulin G ; Immunosuppressive Agents
Language	English
Publishing date	2017-07-10
Publishing country	Netherlands
Document type	Letter
ZDB-ID	779361-3
ISSN	1573-2592 ; 0271-9142
ISSN (online)	1573-2592
ISSN	0271-9142
DOI	10.1007/s10875-017-0410-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1640: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Potential Roles for C1 Inhibitor in Transplantation.

Berger, Mel / Baldwin, William M / Jordan, Stanley C

Transplantation

2015 Volume 100, Issue 7, Page(s) 1415–1424

Abstract: Complement is a major contributor to inflammation and graft injury. This system is especially important in ischemia-reperfusion injury/delayed graft function as well as in acute and chronic antibody-mediated rejection (AMR). The latter is increasingly ... ...

Abstract	Complement is a major contributor to inflammation and graft injury. This system is especially important in ischemia-reperfusion injury/delayed graft function as well as in acute and chronic antibody-mediated rejection (AMR). The latter is increasingly recognized as a major cause of late graft loss, for which we have few effective therapies. C1 inhibitor (C1-INH) regulates several pathways which contribute to both acute and chronic graft injuries. However, C1-INH spares the alternative pathway and the membrane attack complex (C5-9) so innate antibacterial defenses remain intact. Plasma-derived C1-INH has been used to treat hereditary angioedema for more than 30 years with excellent safety. Studies with C1-INH in transplant recipients are limited, but have not revealed any unique toxicity or serious adverse events attributed to the protein. Extensive data from animal and ex vivo models suggest that C1-INH ameliorates ischemia-reperfusion injury. Initial clinical studies suggest this effect may allow transplantation of donor organs which are now discarded because the risk of primary graft dysfunction is considered too great. Although the incidence of severe early AMR is declining, accumulating evidence strongly suggests that complement is an important mediator of chronic AMR, a major cause of late graft loss. Thus, C1-INH may also be helpful in preserving function of established grafts. Early clinical studies in transplantation suggest significant beneficial effects of C1-INH with minimal toxicity. Recent results encourage continued investigation of this already-available therapeutic agent.
MeSH term(s)	Angioedema/therapy ; Animals ; Complement C1 Inhibitor Protein/therapeutic use ; Complement System Proteins/physiology ; Graft Rejection/blood ; Graft Rejection/immunology ; Graft Survival ; Humans ; Inflammation ; Primary Graft Dysfunction/drug therapy ; Reperfusion Injury ; Transplantation
Chemical Substances	Complement C1 Inhibitor Protein ; Complement System Proteins (9007-36-7)
Language	English
Publishing date	2015-02-03
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	208424-7
ISSN	1534-6080 ; 0041-1337
ISSN (online)	1534-6080
ISSN	0041-1337
DOI	10.1097/TP.0000000000000995
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 488: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 509: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito